RSV Polyanhydride Nanoparticle Vaccine
Summary
The USPTO published patent application US20260096999A9 for a respiratory syncytial virus (RSV) vaccine using polyanhydride nanoparticle delivery technology. The application, filed February 17, 2022 by inventors Steven M. Varga and Kevin L. Legge, claims vaccine compositions including RSV F protein in pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles, with optional adjuvant. Patent applications are published to inform the public and allow monitoring of emerging IP positions in the pharmaceutical sector.
What changed
The USPTO published patent application US20260096999A9 disclosing vaccine compositions against respiratory syncytial virus using biodegradable polyanhydride polymer particles as a delivery vehicle for RSV F and/or M proteins. The claimed invention includes pre-fusion stabilized F protein forms and optional adjuvants for enhanced immune response.\n\nFor vaccine developers, pharmaceutical manufacturers, and researchers in the RSV immunotherapy space, this publication signals a potential IP position covering polyanhydride nanoparticle-based RSV vaccines. Parties developing similar delivery technologies or RSV vaccine candidates should review the claims upon grant and monitor prosecution history for scope and validity.
What to do next
- Monitor for updates
- Review patent claims if developing similar vaccines
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYANHYDRIDE NANOPARTICLE VACCINE
A9 US20260096999A9 Kind: A9 Apr 09, 2026
Inventors
Steven M. Varga, Kevin L. Legge
Abstract
Disclosed are compositions and methods for vaccinating susceptible individuals against infection by respiratory syncytial virus (RSV). The disclosed compositions include vaccine compositions comprising an effective amount of respiratory syncytial virus (RSV) F protein in a pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles for inducing an immune response against RSV. The vaccine compositions also may include a suitable adjuvant.
CPC Classifications
A61K 9/5146 A61K 9/0048 A61K 31/7105 A61K 31/713 A61K 39/155 A61K 39/39 A61P 31/14 C12N 7/00 C12N 15/113 C12N 15/1136 A61K 2039/55561 C12N 2310/14 C12N 2310/321 C12N 2320/30 C12N 2320/31 C12N 2760/18534
Filing Date
2022-02-17
Application No.
17674683
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.